Nyxoah Issues First Half 2021 Financial Results

REGULATED INFORMATION

Nyxoah Issues First Half 2021 Financial Results

Mont–Saint–Guibert, Belgium "" August 31, 2021, 10:30pm CET / 4:30pm ET "" Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced its unaudited condensed consolidated interim financial statements for the first half of 2021.

Highlights

  • $97.8 million Nasdaq IPO gross proceeds
  • On track to complete US DREAM trial enrollment
  • 355 thousand revenue generated in Europe, compared to no revenue for the six months ended June 30, 2020, driven mainly in Germany
  • Increased commercial activities in Germany with 12 active accounts in Q2, up from 2 in Q1 2021
  • Announced BETTER SLEEP study top–line results that showed primary safety and performance endpoints met, with statistically significant mean reduction in the AHI score in full patient population including Complete Concentric Collapse ("CCC") patients
  • To submit full BETTER SLEEP study data to a medical journal for publication and announce results following further analyses
  • Integrated Vanderbilt University technology into our scientific and technology department pipelines including collaboration with US and German key opinion leaders

"In the first half of 2021, we kept pace with our initiatives to deliver significant new accomplishments. In less than 12 months, we completed our second IPO with a Nasdaq listing, further strengthening our balance sheet; made important gains in commercial activities in Germany, our initial commercial proof of concept market; advanced clinical programs, including data to potentially expand our addressable market to include CCC patients; and maintained focused investments in new products and technologies," said Olivier Taelman, CEO of Nyxoah. "In the second half, we look forward to further accelerating our commercial activities in existing markets, enter new markets, scale up, and advance clinical programs, including enrollment completion of our US DREAM study in the fourth quarter."

First Half 2021 Results

For the six months ended
June 30
2021 2020
(in thousands)
Revenue 355 '
Cost of goods sold (115) '
Gross profit 240 '
General and administrative expenses (4 777) (2 400)
Research and development expenses (1 255) (56)
Clinical expenses (631) (509)
Manufacturing expenses (2 171) (207)
Quality assurance and regulatory expenses (642) (86)
Patents fees & Related (793) (107)
Therapy Development expenses (1 502) (761)
Other operating income / (expenses), net (97) 184
Operating loss for the period (11 628) (3 942)
Financial income 43 82
Financial expense (899) (416)
Loss for the period before taxes (12 484) (4 276)
Income taxes (124) (24)
Loss for the period (12 608) (4 300)
Loss attributable to equity holders (12 608) (4 300)
Other comprehensive loss
Items that may be subsequently reclassified to profit or loss (net of tax)
Currency translation differences 192 (89)
Total comprehensive loss for the year, net of tax (12 416) (4 389)
Loss attributable to equity holders (12 416) (4 389)
Basic Earnings Per Share (in EUR) (0.570) (0.262)
Diluted Earnings Per Share (in EUR) (0.570) (0.262)

Revenue

Revenue was 355 thousand for the six months ended June 30, 2021, compared to no revenue for the six months ended June 30, 2020. The increase in revenue was attributable to the Company's commercialization of the Genio system mainly in Germany, and to a lesser extent, Spain and Belgium.

Cost of Goods Sold

Cost of goods sold was 115 thousand for the six months ended June 30, 2021, compared to no cost for the six months ended June 30, 2020. The increase in cost of goods sold was attributable to the sales of the Genio system in Europe.

General and Administrative Expenses. General and administrative expenses increased by 2.4 million, or 99 %, from 2.4 millionfor the six months ended June 30, 2020 to 4.8 million for the six months ended June 30, 2021 mainly due to an increase in consulting and contractors' fees. The increase in consulting and contractors' fees includes variable compensations for an amount of 0.3 million for the six months ended June 30, 2020 and 1.9 million for the six months ended June 30, 2021 related to a cash–settled share based payment transaction and an increase of consultant services to support the company in legal, finance, tax and IT matters.

Research and Development Expenses. Before capitalization of 0.6 million for the six months ended June 30, 2021 and 0.6 million for the six months ended June 30, 2020, research and development expenses increased by 1.1 million or 173 %, from 0.7 million for the six months ended June 30, 2020, to 1.8 million for the six months ended June 30, 2021, due to an increase in staff and consulting costs to support our R&D activities. The Company started as of January 2021 to amortize its intangible assets. This explains the significant increase of depreciation expenses for the six months ended June 30, 2021, compared to the six months ended June 30, 2020.

Clinical Expenses. Before capitalization of 3.1 million for the six months ended June 30, 2021, and 1.4 million for the six months ended June 30, 2020, clinical expenses increased by 1.8 million, or 96%, from 1.9 million for the six months ended June 30, 2020, to 3.7 million for the six months ended June 30, 2021. The increase in the expenses was mainly due to an increase in staff and consulting to support the completion of the BETTER SLEEP trial implantations, continuous recruitment for the EliSA trial and the ongoing DREAM IDE trial in the United States.

Manufacturing Expenses. Before capitalization of 0.3 million for the six months ended June 30, 2021, and 1.2 million for the six months ended June 30, 2020, manufacturing expenses increased by 1.0 million, or 72% from 1.4 million for the six months ended June 30, 2020, to 2.4 million for the six months ended June 30, 2021. The increase in the expenses was mainly due to an increase in staff, in production and engineering team to support capacity and yield improvement. In addition, manufacturing expenses increased for the six months ended June 30, 2021, compared to the same period of 2020 due to the increase demand of our Genio system for non–commercial purposes (clinical trials, development activities, etc) and, therefore, the increase of associated production costs.

Quality Assurance and Regulatory Expenses. Before capitalization of 0.2 million for the six months ended June 30, 2021, and 0.5 million for the six months ended June 30, 2020, quality assurance and regulatory expenses increased by 0.3 million, or 44% from 0.6 million for the six months ended June 30, 2020, to 0.9 million for the six months ended June 30, 2021. The increase in the expenses was mainly due to an increase in staff and QA & regulatory activities to support manufacturing scaling up process.

Patent Fees & Related Expenses. Before capitalization of 0.2 million for the six months ended June 30, 2020, patents fees and related expenses increased by 0.5 million, or 199 % from 0.3 million for the six months ended June 30, 2020, to 0.8 million for the six months ended June 30, 2021, due to expenses related the in–licensing agreement with Vanderbilt University.

Therapy Development Expenses. Therapy development expenses increased by 0.7 million or 97 % from 0.8 million for the six months ended June 30, 2020, to 1.5 million for the six months ended June 30, 2021. The increase in the expenses was mainly due to an increase in staff and consulting, to support the launch of the commercialization in Europe.

Other Operating Income / (Expenses). The Company had other operating expenses of 0.1 million for the six months ended June 30, 2021, and other operating income of 0.2 million for the six months ended June 30, 2020, the evolution being mainly due to the impact of the initial measurement and re–measurement of the financial debt.

Operating Loss

The Company realized a net loss of 12.6 million for the six months ended June 30, 2021, compared to a net loss of 4.3 million for the six months ended June 30, 2020, due to increases of activities in all departments.

Cash Position

Cash and cash equivalents totaled 79.2 million on June 30, 2021, as compared to 23.9 million on June 30, 2020.

Net cash used in operations was 8.4 million for the six months ended June 30, 2021 compared to 4.0 million for the six months ended June 30, 2020. The increase of 4.3 million was primarily due to an increase in a loss for the period of 8.2 million that was mainly attributable to increased general and administrative expenses, research and development expenses, manufacturing expenses and therapy development expenses, which were offset by a positive variation in the working capital and other non–cash transactions of 3.9 million.

Net cash used in investing activities was 4.5 million for the six months ended June 30, 2021 compared 3.7 million to the six months ended June 30, 2020.

Net cash used in financing activities for the six months ended June 30, 2021 was 289 thousand compared to 25.7 million of net cash provided by financing activities during the six months ended June 30, 2020. The decrease was due to the fact that no financing rounds have been organized in the first half of 2021.

Outlook for 2021

The Company's business, operational, and clinical outlook for 2021 include the following expected milestones and goals:

  • Begin marketing in Switzerland with approved DRG, as well as additional European countries by the second half of 2021
  • Ramp up EU revenue through dedicated sales team in Germany
  • Open second independent manufacturing site in Belgium
  • Complete DREAM pivotal trial enrollment in the fourth quarter of 2021

First half–year report 2021
Nyxoah's financial report for the first half of 2021, including details of the unaudited condensed consolidated financial statements, are available on the investor page of Nyxoah's website (https://investors.nyxoah.com/financials).

Conference call and webcast presentation
Nyxoah will conduct a conference call to open to the public tomorrow, September 1, 2021, at 3:00 p.m. CET / 9:00 a.m. ET, which will also be webcasted. To participate in the conference call, please dial one of the following numbers:

Conference ID: 7468474

USA: (844) 260–3718
Belgium: 0800 73264
International: (929) 517–0938

A question–and–answer session will follow the presentation of the results. To access the live webcast, go to https://investors.nyxoah.com/events. The archived webcast will be available for replay shortly after the close of the call.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah's lead solution is the Genio system, a CE–validated, patient–centered, next generation hypoglossal neurostimulation therapy for OSA, the world's most common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Following the successful completion of the BLAST OSA study in patients with moderate to severe OSA, the Genio system received its European CE Mark in 2019. The Company has completed the BETTER SLEEP study in Australia and New Zealand for therapy indication expansion and is currently conducting the DREAM IDE pivotal study for FDA approval and a post–marketing EliSA study in Europe to confirm the long–term safety and efficacy of the Genio system.

For more information, please visit http://www.nyxoah.com/.

Caution "" CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward–looking statements
Certain statements, beliefs and opinions in this press release are forward–looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations regarding the Genio system; planned and ongoing clinical studies of the Genio system; the potential advantages of the Genio system; Nyxoah's goals with respect to the development, regulatory pathway and potential use of the Genio system; the utility of clinical data in potentially obtaining FDA approval of the Genio system; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward–looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward–looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward–looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward–looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward–looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward–looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward–looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward–looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward–looking statements, which speak only as of the date of this press release.

Contacts:
Nyxoah
Fabian Suarez, Chief Financial Officer
corporate@nyxoah.com
+32 (0)10 22 24 55

Gilmartin Group
Vivian Cervantes
IR@nyxoah.com

Attachment


Dante Labs Announces Appointment of Sandra Close to its Board of Directors to Support Strategic Initiatives in Diagnostics

CAMBRIDGE, United Kingdom, Aug. 31, 2021 (GLOBE NEWSWIRE) — Dante Labs, a global leader in genomics and precision medicine, announced today the appointment of Sandra Close, Ph.D., as a member of its Board of Directors. Sandra was formerly the Chief Diagnostics Strategy Officer at Invitae, a leading medical genetics company, which acquired ArcherDX in 2020.

"I'm thrilled to welcome Sandra Close to the Dante Labs Board," said Dante Labs CEO Andrea Riposati. "Sandra's expertise in leading strategic efforts to provide actionable, more personalized medical information have had real life impact on people's healthcare decisions, and her leadership in the field will be a valuable addition to our board as we expand the capabilities of the diagnostics side of our business."

Dr. Close stated, "I'm very pleased to be joining Dante's Board at this exciting time to help accelerate diagnostics in healthcare, particularly in rare disease and oncology where earlier intervention is so essential to better health outcomes."

Dr. Close is an experienced leader in driving quality, regulatory and business strategy for growing diagnostics companies on a global scale. Her work at Invitae was focused on leading diagnostics strategy efforts on the oncology team, having joined Invitae through the acquisition of ArcherDX, where she served as Executive Vice President of Quality, Regulatory and Business Strategy. Prior to that, Dr. Close served as CEO and Independent Consultant at GenEngine, an information company providing genetics support technology and services. Prior to her work at GenEngine, Dr. Close held several roles in biotechnology and biopharma. Dr. Close will join Illumina Chief Operations Officer Bob Ragusa, GRAIL SVP Mark Morgan and Pacific Biosciences Chief Operating Officer Mark Van Oene to Dante Labs Board of Directors.

About Dante Labs
Dante Labs is a global genomic data company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. Our assets include one of the largest private genome databases with research consent, a proprietary software platform designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

Headquartered in Cambridge, United Kingdom, with a research laboratory in Wolverhampton, Dante Labs supported the UK Government's urgent requirement to scale–up a high–capacity, highly automated testing solution for Covid–19, including infected patients as well as those with antibodies. Dante Labs was able to deliver by leveraging existing technology that had been developed for whole genome sequencing.

Contact
Giorgio Lodi
media@dantelabs.com
+39 0862 191 0671
www.dantelabs.com


Allow Least Developed Countries to Develop

By Anis Chowdhury and Jomo Kwame Sundaram
SYDNEY and KUALA LUMPUR, Aug 31 2021 - The pandemic is pushing back the world’s poorest countries with the least means to finance economic recovery and contagion containment efforts. Without [...] Read more »